How India Exports Telmisartan to the World

In the United States, telmisartan is approved for the treatment of hypertension and to reduce cardiovascular risk. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for telmisartan, indicating a competitive generic market. Notably, the FDA approved an ANDA for telmisartan tablets by Aurobindo Pharma Limited in March 2025. As of March 2026, there are no active import alerts related to telmisartan, facilitating its importation into the U.S. market. The substantial number of Indian exporters (413) underscores India's significant role in supplying telmisartan to the U.S., reflecting the country's robust pharmaceutical manufacturing capabilities.

In the European Union, telmisartan is authorized for treating essential hypertension and reducing cardiovascular morbidity. The European Medicines Agency (EMA) has approved various telmisartan-containing products, including generics like Telmisartan Actavis, authorized on 30 September 2010. However, on 19 May 2021, the European Commission withdrew the marketing authorization for Telmisartan Teva at the request of the marketing authorization holder, Teva B.V., due to commercial reasons. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) continues to regulate telmisartan post-Brexit, adhering to standards comparable to the EMA's. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting telmisartan to these markets.

Telmisartan is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in managing hypertension globally. The WHO Prequalification Programme has assessed and prequalified certain telmisartan products, ensuring they meet international quality standards. Telmisartan's specifications are detailed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), providing standardized quality benchmarks for its production and quality control.

In India, telmisartan is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for telmisartan tablets to ensure affordability; the latest revision was in August 2025. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products; however, telmisartan is generally exempt from this requirement, facilitating its export process.

The primary patents for telmisartan have expired, leading to a competitive generic market with multiple manufacturers producing and exporting the drug. This has resulted in increased availability and reduced prices globally, benefiting healthcare systems and patients.

In June 2025, the NPPA revised the ceiling price for telmisartan tablets, reducing it by 5% to enhance affordability. In September 2025, the EMA approved a new fixed-dose combination of telmisartan and amlodipine for hypertension treatment, expanding therapeutic options. In December 2025, the WHO updated its Model List of Essential Medicines, reaffirming telmisartan's inclusion, highlighting its continued relevance in global health. In February 2026, the CDSCO issued new guidelines for the bioequivalence studies of telmisartan, aiming to ensure consistent quality among generics. In March 2026, the FDA conducted inspections of Indian manufacturing facilities producing telmisartan, emphasizing compliance with GMP standards.

These developments reflect ongoing efforts by regulatory authorities to ensure the quality, safety, and affordability of telmisartan, reinforcing its critical role in managing hypertension worldwide.

India's pharmaceutical industry, including the production of Telmisartan, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. As of 2019, approximately 68% of India's API imports originated from China, highlighting a significant dependency on Chinese suppliers. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and environmental regulations affecting Chinese manufacturing.

In response, the Indian government launched the Production Linked Incentive (PLI) scheme in 2020, aiming to bolster domestic API and KSM production. By November 2024, this initiative led to the inauguration of two greenfield plants dedicated to manufacturing critical molecules like Penicillin G and Clavulanic Acid, essential for antibiotic production. These efforts are projected to reduce India's import dependence on key pharmaceutical ingredients by half. However, the transition to self-sufficiency is ongoing, and the industry remains vulnerable to external supply disruptions in the interim.

Our proprietary trade data from 2022 to 2026 reveals a high supplier concentration in Telmisartan exports from India. The top five exporters account for 99.3% of the total export value, with CIPLA LIMITED alone contributing 98.4% ($10,800.1 million USD). This dominance indicates a significant single-source risk, as any operational or regulatory issues affecting CIPLA LIMITED could severely disrupt the global supply of Telmisartan.

While the PLI scheme has incentivized diversification and increased domestic production capacity, the current market dynamics underscore the need for broader participation among manufacturers to mitigate single-source vulnerabilities.

Recent geopolitical events have further strained the pharmaceutical supply chain. In March 2026, the Strait of Hormuz crisis led to a near-complete halt of oil tanker movements, disrupting global trade routes and causing significant delays in the shipment of pharmaceuticals from India. Additionally, heightened tensions in the Red Sea and the Suez Canal have forced shipping companies to reroute vessels around Africa's Cape of Good Hope, resulting in longer transit times and increased shipping costs.

These disruptions have not only delayed deliveries but also escalated costs, impacting the availability and pricing of essential medications like Telmisartan in destination markets.

• Diversify Supplier Base: Encourage the development and support of multiple manufacturers for Telmisartan to reduce dependency on a single supplier.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme to boost domestic API and KSM manufacturing capabilities, reducing reliance on imports.

• Strengthen Supply Chain Resilience: Develop contingency plans and alternative logistics strategies to navigate geopolitical disruptions, ensuring consistent delivery of pharmaceuticals.

• Monitor Regulatory Compliance: Regularly assess and ensure compliance with international quality standards to prevent regulatory actions that could disrupt supply chains.

• Invest in Alternative Shipping Routes: Explore and invest in diversified shipping routes and methods to mitigate risks associated with geopolitical tensions affecting traditional maritime pathways.

RISK_LEVEL: HIGH